TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages

BMC Cancer

Bao-Zhu Yuan⁴  Joshua Chapman³  Min Ding³  Junzhi Wang¹  Binghua Jiang²  Yon Rojanasakul²  Steven H Reynolds³ 

[1] National Institutes for Food and Drug Control, Beijing, 100050, China

[2] Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, 26506, USA

[3] National Institute for Occupational Safety and Health, CDC, Morgantown, WV, 26505, USA

[4] Department of Cell Biology, National Institute for Food and Drug Control, 2 Tiantan Xili, Dongcheng District, Beijing, 100038, China

关键词: Akt;    Mcl-1;    Proteasome inhibitor;    Trail;    Apoptosis;    Malignant pleural mesothelioma;   

Others  :  1079850
DOI  :  10.1186/1471-2407-13-140

 received in 2012-08-28, accepted in 2013-03-12,  发布年份 2013

【 摘 要 】

Background

Malignant pleural mesothelioma (MPM) is an aggressive malignancy closely associated with asbestos exposure and extremely resistant to current treatments. It exhibits a steady increase in incidence, thus necessitating an urgent development of effective new treatments.

Methods

Proteasome inhibitors (PIs) and TNFα-Related Apoptosis Inducing Ligand (TRAIL), have emerged as promising new anti-MPM agents. To develop effective new treatments, the proapoptotic effects of PIs, MG132 or Bortezomib, and TRAIL were investigated in MPM cell lines NCI-H2052, NCI-H2452 and NCI-H28, which represent three major histological types of human MPM.

Results

Treatment with 0.5-1 μM MG132 alone or 30 ng/mL Bortezomib alone induced a limited apoptosis in MPM cells associated with the elevated Mcl-1 protein level and hyperactive PI3K/Akt signaling. However, whereas 10–20 ng/ml TRAIL alone induced a limited apoptosis as well, TRAIL and PI combination triggered a robust apoptosis in all three MPM cell lines. The robust proapoptotic activity was found to be the consequence of a positive feedback mechanism-governed amplification of caspase activation and cleavage of both Mcl-1 and Akt proteins, and exhibited a relative selectivity in MPM cells than in non-tumorigenic Met-5A mesothelial cells.

Conclusion

The combinatorial treatment using TRAIL and PI may represent an effective new treatment for MPMs.

【 授权许可】

   
2013 Yuan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Antman KH: Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981, 8:313-320.
• [2]Price B: Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997, 145:211-218.
• [3]Goudar RK: New therapeutic options for mesothelioma. Curr Oncol Rep 2005, 7:260-265.
• [4]Krug LM: An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005, 19:1117-1136. vii
• [5]Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
• [6]Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL: Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300-2304.
• [7]Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R: Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007, 18:1196-1202. Epub 2007 Apr 1111
• [8]Bolukbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J: Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with Cisplatin/Permetrexed and radiotherapy. Lung Cancer 2009, 74:75-85.
• [9]Makin G, Dive C: Apoptosis and cancer chemotherapy. Trends Cell Biol 2001, 11:S22-S26.
• [10]Cryns V, Yuan J: Proteases to die for. Genes Dev 1998, 12:1551-1570.
• [11]Green DR: At the gates of death. Cancer Cell 2006, 9:328-330.
• [12]Jiang X, Wang X: Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004, 73:87-106.
• [13]Cory S, Huang DC, Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
• [14]Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
• [15]Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
• [16]Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W: PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008, 33:502-506.
• [17]Aldieri E, Orecchia S, Ghigo D, Bergandi L, Riganti C, Fubini B, Betta PG, Bosia A: Simian virus 40 infection down-regulates the expression of nitric oxide synthase in human mesothelial cells. Cancer Res 2004, 64:4082-4084.
• [18]Carbone M, Pass HI, Miele L, Bocchetta M: New developments about the association of SV40 with human mesothelioma. Oncogene 2003, 22:5173-5180.
• [19]Pass HI, Donington JS, Wu P, Rizzo P, Nishimura M, Kennedy R, Carbone M: Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences. J Thorac Cardiovasc Surg 1998, 116:854-859.
• [20]Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L, Gaudino G: SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005, 65:5256-5262.
• [21]Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
• [22]Henderson CJ, Aleo E, Fontanini A, Maestro R, Paroni G, Brancolini C: Caspase activation and apoptosis in response to proteasome inhibitors. Cell Death Differ 2005, 12:1240-1254.
• [23]Yuan B, Chapman J, Reynolds SH: Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage. Oncogene 2009, 28:3775-3786.
• [24]Yuan B-Z, Chapman JA, Reynolds SH: Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Translational Oncology 2008, 1:129-140.
• [25]Finnberg N, El-Deiry WS: TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 2008, 7:1525-1528.
• [26]Johnstone RW, Frew AJ, Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008, 8:782-798.
• [27]Sayers TJ, Murphy WJ: Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006, 55:76-84.
• [28]Das T, Sa G, Sinha P, Ray PK: Induction of cell proliferation and apoptosis: dependence on the dose of the inducer. Biochem Biophys Res Commun 1999, 260:105-110.
• [29]Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P: Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998, 17:313-325.
• [30]Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC, Reynolds SH: DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004, 23:1405-1411.
• [31]Yuan BZ, Jefferson AM, Millecchia L, Popescu NC, Reynolds SH: Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp Cell Res 2007, 313:3868-3880.
• [32]Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8:945-954.
• [33]Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, Hemmings BA: Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase–significance for diabetes and cancer. Pharmacol Ther 1999, 82:409-425.
• [34]Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X: Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003, 17:1475-1486.
• [35]Zhong Q, Gao W, Du F, Wang X: Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005, 121:1085-1095.
• [36]Weng C, Li Y, Xu D, Shi Y, Tang H: Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 2005, 280:10491-10500.
• [37]LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008, 11:32-50.
• [38]Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005, 19:1294-1305.
• [39]Franke TF, Cantley LC: Apoptosis. A Bad kinase makes good. Nature 1997, 390:116-117.
• [40]He YY, Huang JL, Gentry JB: Chignell. Epidermal growth factor receptor down-regulation induced by UVA in human keratinocytes does not require the receptor kinase activity. J Biol Chem 2003, 278:42457-42465.
• [41]Pinton G, Manente AG, Angeli G, Mutti L, Moro L: Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axix in malignant pleural mesothelioma. PloS One 2012, 7:1-7.